Lee and Yoon, Br J Pharmacol, 2012
- Post by: admin
- 3:29PM Apr 02, 2013
- Comments off
Division of Cardiology, Department of Medicine, Emory University School of Medicine, 1639 Pierce Drive, WMRB 3309, Atlanta, GA 30322, USA.
Cell-based therapy has emerged as a promising therapy for cardiovascular disease. Particularly bone marrow (BM)-derived cells have been most extensively investigated and shown encouraging results in preclinical studies. Clinical trials, however, have demonstrated split results in post-myocardial infarction (MI) cardiac repair. Mechanistically, transdifferentiation of BM-derived cells into cardiovascular tissue demonstrated by earlier studies is now known to play a minor role in functional recovery, and humoral and paracrine effects turned out to be main mechanisms responsible for tissue regeneration and functional recovery. With this advancement in the mechanistic insight of BM-derived cells, new efforts have been made to identify cell population, which can be readily isolated and obtained in sufficient quantity without mobilization and have higher therapeutic potential. Recently, hematopoietic CD31(+) cells, which are more prevalent in bone marrow and peripheral blood, have been revealed to have angiogenic and vasculogenic activities and strong potential for therapeutic neovascularization in ischemic tissues. This article will cover the recent advances in BM-derived cell-based therapy and implication of CD31(+) cells.